HLA-C and neoplasm: We conclude that the MHCI/II deficient tumor cell lines generated by the CRISPR/Cas9 technology might serve as parental lines for the establishment of MHC compatible, transplantable tumor models in HLA-transgenic mouse strains devoid of endogenous MHC molecule expression.